Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorGalderma R&D

About this trial

The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.

Eligibility criteria

Qualifiers

Males or non-pregnant, non-breastfeeding females, 22 years of age or older.

Intent to receive treatment for augmentation and correction of retrusion in the chin region.

Disqualifiers

Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.

Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.

Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.

Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale.

Trial design

Treatments tested in this trial

  • Restylane Lyft with Lidocaine

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators